Quick Summary — ICCC scores higher on quality with 7.0/10 vs IFRX's 1.8/10. ICCC trades at $9.79 while IFRX trades at $2.17. Both analyzed daily using SEC EDGAR data across 13 institutional models.
ICCC scores higher with a 7.0/10 quality rating vs IFRX's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $9.79, ICCC trades +89.3% above its Bayesian DCF fair value of $1.05, while IFRX at $2.17 trades +74.0% above its estimate of $0.56. ICCC shows a wider gap between price and intrinsic value.
ICCC earns a Quality of Company score of 7.0/10 compared to IFRX's 1.8/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both ICCC and IFRX to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both ICCC and IFRX operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ICCC vs IFRX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.